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New polymeric calcium phosphate cement composites (CPCs) were developed. Cement powder consisting of 60wt% tetracalcium
phosphate, 30wt% dicalcium phosphate dihydrate, and 10wt% tricalcium phosphate was combined with either 35%w/w poly
methyl vinyl ether maleic acid or polyacrylic acid to obtain CPC-1 and CPC-2. The setting time and compressive and diametral
tensile strength of the CPCs were evaluated and compared with that of a commercial hydroxyapatite cement. In vitro cytotoxicity
and in vivo biocompatibility of the two CPCs and hydroxyapatite cement were assessed. The setting time of the cements was 5–
15min. CPC-1 and CPC-2 showed signiﬁcantly higher compressive and diametral strength values compared to hydroxyapatite
cement. CPC-1 and CPC-2 were equivalent to Teﬂon controls after 1 week. CPC-1, CPC-2, and hydroxyapatite cement elicited a
moderate to intense inﬂammatory reaction at 7 days which decreased over time. CPC-1 and CPC-2 show promise for orthopedic
applications.
1.Introduction
There is a high clinical demand for synthetic bone substi-
tution materials, due to drawbacks associated with biolog-
ical bone grafts. Xenografts are generally associated with
potential infections. The same is true for allografts, where
there are concerns regarding antigenicity and transmission
of infectious diseases in spite of rigorous control on the
selection of donors and the preparation of the graft. Thus,
interest in synthetic implant materials for bone grafting has
been on the rise
According to Reuger, there are diﬀerent classes of bone
substitute materials which are very prominent in ceram-
ics [1]. The basis of these substitutes is usually calcium
phosphate, due to its good biocompatibility because of its
similarity to the mineral phase of natural bone tissue [2].
The search for better results has led to modiﬁcations in the
sintering process by which these materials are formed. These
modiﬁcations result in multiple forms of calcium phosphate
materials, with variations in the calcium-to-phosphate rate
and porosity, which can aﬀect both biocompatibility and
mechanical resistance. One such variation is calcium phos-
phate cement (CPC), a term introduced by Groninger et
al. [3]. According to these authors, CPC consists of two
components, one basic and one acidic which react when
mixed with water, producing one or more products with an
intermediate acidity.
Calcium phosphate cements can easily adapt to the shape
of bone cavities and defects leading to a close apposition to
the host tissue with osseointegrative properties comparable
to or better than bulk CPCs [4]. The hardening of the
cement, which usually consists of an aqueous solution2 International Journal of Biomaterials
and one or several calcium phosphates, occurs at a low
temperature through a setting reaction that leads to the
in situ formation of a solid calcium phosphate [5]. A
number of CPCs currently are available commercially [6–
8]. However, due to their limited compressive strength, they
are restricted primarily to nonstress-bearing applications.
These include uses in maxillofacial surgery, the repair
of cranial defects, and dental ﬁllings [6–8]. In order to
improve the mechanical properties of CPCs, a number
of researchers have blended polymers with CP cements
and met with promising results. Durucan and Brown
[9, 10]m a d eα-tricalcium phosphate/polylactic acid (α-
TCP/PLA) and α-TCP/polylactic-coglycolic acid (PLGA)
blends with a subsequent hydrolysis of α-TCP to calcium-
deﬁcient hydroxyapatite (CDHA), which showed a modest
improvement over the pure cement. Fujishiro et al. [11]
added gelatin to their cement formulations, primarily to
stabilize the pastes in aqueous solution before it develops
adequate rigidity, and found that they were able to get
more than a 50% improvement of the compressive strength.
They also demonstrated an improvement in mechanical
properties by adding rod-like hydroxyapatite and Perovskite
(CaTi03) powders to the cements. Miyazaki et al. [12, 13]
used a number of polymers including polyacrylic acid (PAA)
and polyvinyl alcohol (PVA), to improve the properties
of tetracalcium phosphate-dicalcium phosphate dehydrate
(TTCP-DCPD) cement. They noted marked increases (up
to three-fold) in mechanical properties, but an unacceptable
reduction of workability and setting time. Dos Santos et
al. [14] reported similar results using sodium alginate and
sodium polyacrylate.
Matsuya et al. [15] reported on the reaction of a less
reactive polyacid (the hydrolysis product of 1:1 copoly-
mer of methyl vinyl ether and maleic anhydride) with
calciumphosphatecement(CPC)ortetracalciumphosphate
(TTCP). This commercial copolymer, which is oﬀered in
several molecular weights, can be dissolved with hydrolysis
of the anhydride groups in water to form the corresponding
maleic acid copolymer, polymethyl-vinyl ether-maleic acid.
It is known to have a number of nondental applications
(hair sprays, surgical adhesives), which suggests potentially
favorable biocompatibility for dental and other biomedical
uses. The cement forming reaction was signiﬁcantly faster
than that of a water setting CPC but slower than that
observed with the mixed powder and polyacryclic acid. The
diametral tensile strength and compressive strength of this
polymeric calcium phosphate cement (CPC) at 24hrs and
after storage in distilled water were 13.7MPa and 71MPa,
respectively.
In light of the preceding discussion, we endeavored
to improve the mechanical and physical properties of the
cement by adding water soluble polymers during set-
ting. Drawing in results from the literature gave us our
candidate polymer components. In the present study, we
tested a hypothesis that incorporation of polymeric acids
into traditional calcium phosphate cements (CPCs) would
produce formulations with improved handling, setting, and
mechanical and biologic properties to permit orthopedic
applications. The present study tests this hypothesis by
measuring the initial and ﬁnal setting time of two novel
CPC formulations derived from a mixture of CPC powder
with two aqueous solutions of polymeric acids, polyacrylic
acid, and 35%w/w polymethyl-vinyl ether-maleic acid as
comparedtoacommerciallyavailablehydroxyapatitecement
(Bone Source, StrykerLeibinger Gmb & Co. KG, Freiburg,
Germany). The compressive and diametral tensile strength
of these two polymeric formulations compared to hydrox-
yapatite cement. To evaluate comparatively, the cytotoxic
properties of the two novel CPC formulations and commer-
cially available hydroxyapatite cement on an osteoblast cell
line (ROS17/2.8) and the biocompatibility of these materials
following implantation into the subcutaneous connective
tissue of rats.
2.MaterialsandMethods
Twocalciumphosphatecementsandcommercialhydroxyap-
atitecement(BoneSource,StrykerLeibingerGmb&Co.KG,
Freiburg, Germany) were prepared and evaluated (Table 1).
The cement formulations were as follows.
(a) Calcium phosphate cement was derived from a
mixture of 60wt% tetracalcium phosphate, 30wt%
dicalcium phosphate dehydrate, and 10wt% trical-
cium phosphate.
(b) Two types of aqueous solutions of acids were used
for mixing the powder to formulate the calcium
phosphate cements.
2.1.PreparationofCalciumPhosphateCementPowder. Tetra-
calcium phosphate powder was synthesized from a solid
state reaction between calcium hydrogen orthophosphate
anhydrous (CaHPO4) and calcium carbonate, then ground
a n ds i e v e dt oo b t a i na na v e r a g ep a r t i c l es i z eo f1 μmt o
80μm. Dicalcium phosphate dehydrate powder (DCPD) was
obtained from monocalcium phosphate and calcium oxide,
which were crushed separately in an agate mortar to obtain
an average particle size of 80μm. Tricalcium phosphate
Ca3(PO4)2 was prepared by a crystallization method from
aqueous solutions of 0.9M calcium nitrate (Ca(NO3)2 ·
4H 2O and 0.6M ammonium phosphate (NH4)2HP04,
which were simultaneously mixed. The reaction pH was
maintained between 5 and 6 by the addition of ammonia
solution.
The precipitated powder was stored for 24hr at
room temperature, then washed with deionized water and
lyophilized. The subsequent calcinations of the resulting
powders were obtained at 900◦Cf o ro v e r1 h r .T h et e t r a -
calcium phosphate, dicalcium phosphate dihydrate and
tricalcium phosphate were then mixed at a molar ratio
1:1:1inablender(DynamicsCorporationofAmerica,New
Hartford, CT) to form the CPC powder.
2.2. Preparation of Aqueous Solution of Liquids. Two types
of liquids previously mentioned in Table 1 were mixed
with the calcium phosphate powder: 35% (w/w) aqueous
solution of polymethyl-vinyl ether-maleic acid was prepared
by dissolving 35 grams of polymethyl-vinyl ether-maleicInternational Journal of Biomaterials 3
Table 1: Composition of the materials used in this study.
Material Composition Trade name Manufacturer
Calcium hydrogen
orthophosphate
anhydrous
Mallinckrodt Baker, Inc.
Phillipsburg, NJ, USA
Calcium carbonate Mallinckrodt Baker, Inc.
Phillipsburg, NJ, USA
Monocalcium
phosphate
monobasic
(MCPM)
Calcium
Phosphate
Monobasic
Sigma Chemical
Laboratories, St. Louis,
MO, USA
Calcium oxide Adwic Laboratory
Chemicals Cairo, Egypt
Calcium nitrate Ca (NO3)2·4H2O
FW 236.15
Sigma Chemical
Laboratories, St. Louis,
MO, USA
Ammonium
phosphate
(NH4)2HPO4 FW
132.06
Sigma Chemical
Laboratories, St. Louis,
MO, USA
Polymethyl-vinyl
ether-maleic
anhydrate
copolymer
(PMVE-Ma)
Sigma Chemical
Laboratories, St. Louis,
MO, USA
Polyacrylic acid
M = 450kDa;
Water content:
2.9wt%
Sigma Chemicals, St. Louis,
MO, USA
Bone Source
Classic
Self-setting
osteoconductive
hydroxyapatite
(HA)
Stryker Leibinger Gmb &
C o .K G ,F r e i b u r g ,G e r m a n y
anhydride (PMVE-MA) copolymer (MW 50,000) in 100mL
ofdistilledwaterat60◦Cfor24hrsinashakerincubator.The
35% w/w aqueous solution of PMVE-Ma was mixed with
CPC powder to form the polymeric CPC cement. 10% (w/w)
aqueous solution of polyacrylic acid (PAA) was prepared
(2mL of PAA solution was added to 2mL of 10% water).
2.3. Preparation of Calcium Phosphate Cements
2.3.1. CPC-1. CPC powder (60wt% tetracalcium phosphate
+ 30wt% dicalcium phosphate dehydrate + 10wt% trical-
cium phosphate). Liquid: 35% (w/w) aqueous solution of
polymethyl-vinyl ether-maleic acid.
2.3.2. CPC-2. CPC powder (60wt% tetracalcium phosphate
+ 30wt% dicalcium phosphate dehydrate + 10wt% trical-
cium phosphate). Liquid: 10% (w/w) aqueous solution of
polyacrylic acid
2.4. Setting Time Measurements. The setting time of the
cements were measured according to the International
Standard ISO 9917 [16] for dental water-based cement.
Ninety seconds after the end of mixing the CPC powders
with liquid, the indenter (300 + 5g in mass, 1 + 0.05mm in
diameter of the needle was carefully lowered vertically on to
the surface of the cement and allowed to remain there for 5s.
Initial setting occurs when a 1mm needle penetrates 25mm
into cement paste. Final set occurs when there is no visible
penetration.Eachtestwasrepeatedﬁvetimesandtheaverage
value was calculated.
2.5. Assessment of the Mechanical Properties of
the Prepared Cements
2.5.1. Preparation of the Compressive Strength Test Specimens.
Steel cylindrical molds with inner diameter of 6mm and
height of 12mm were used to prepare the cement columns
for compressive tests according to the ISO speciﬁcation
no. = 4104[17]forzincpolycarboxylatecement.Thecement
pastes were mixed as previously described and inserted into
a split mold with a release agent to prevent adherence of
the cements. The split mold was covered with a glass plate
for 10min, and then kept undisturbed for another 50min at
37◦C under 100% relative humidity before separation from
the mould [15]. The cylindrical specimens were immersed in
simulated body ﬂuid (SBF) at 37◦C[ 18] for 30min, 1 hour,
4hrs, 24hrs, 1 week, and 2 weeks before the compressive
strengths were measured.
2.5.2. Preparation of the Diametral Strength Specimens. For
the diametral tensile strength test, disc specimens of 6mm
diameter and 3mm height were prepared for each type of4 International Journal of Biomaterials
cement [19]. The specimens were prepared as previously
described for the compressive strength test.
2.6. Testing Procedure. The compressive and diametral
strength tests of each type of cement were determined after
30min, 1 hour, 4hrs, 24hrs, and 4 weeks storage in SBF
using a Universal Testing Machine (Canton, MA, USA)
model no. = 4465 equipped with a 2KN load cell at
a crosshead speed of 0.5mm/minute−1. The compressive
strength was measured by dividing the maximum load in
compression on the ends of the cylindrical specimens by the
original cross-sectional area of the test specimen [20]. The
diametral tensile strength was calculated according to the
equation (DTS = 2P/DT), where P is the applied load, D
is the diameter of the cylinder, and T is the thickness of
the specimen. A sheet of ﬁlter paper (Whatman Type no.
1, Whatman International, Spring –Field Mill, Maidstone,
Kent,England)wasplacedunderneathandanothersheetwas
placed on the top of the specimen during the loading. Each
measurement was repeated six times, and the average value
was calculated. Quantitative data are presented as mean ±
standard deviation and statistical analysis was performed
using a one-way analysis of variance (one-way-ANOVA). A
comparison between two means was made using Tukey’s test,
with statistical signiﬁcance set at P<. 05.
2.7. Cell Culture Experiments
2.7.1. Cytotoxicity Samples. Sample preparation was per-
formed aseptically to prevent the risk of biological con-
tamination during the cytotoxicity testing [21]. Commercial
hydroxyapatite cement was prepared according to the manu-
facturer’s instructions.
Liquids previously mentioned were mixed with calcium
phosphate. The powder liquid to ratio of 4:1 was selected
for the preparation of the three types of cements. This ratio
produced good handling characteristics and working time.
Six discs for each cement (Types I and II CPCs and
Hydroxyapatite cement) were fabricated in sterile Teﬂon
molds 5.5mm in diameter and 3mm thick. The materials
were packed into the mold and allowed to set at room
temperature (25◦C) before testing. Teﬂon discs were used as
an e g a t i v ec o n t r o l .
2.7.2. In Vitro Biological Testing. Materials were tested for in
vitro cytotoxicity in direct contact format (ISO10993) [22]
using ROS 17/2.8 osteoblast-like cells..Cells were maintained
in F-12 medium containing 1.1mM CaCl2 (Allied Chemical
Corporation, Morristown, NJ), 5% Nu Serum (Collabora-
tive Research, Bedford, MA, USA), 25mM L-Glutamine,
and 125units/mL penicillin/streptomycin (GIBCO, Grand
Island, NY, USA). Twenty-fourhrs prior to the addition of
the test specimens, the cells were plated at 30,000cells/cm2
in a 24-well format (Costar, Cambridge, MA, USA) in
1mL of medium per well, then specimens were immediately
(<1min) added to the center of each well and secured such
that the sample could not move. The ratio of the surface
area of the discs to the volume of medium was within the
range of 1.2mm2/mL, as recommended by the International
Standards Organization [23]. The cells and specimens were
incubated at 37◦C for 48hrs in 5% CO2, 95% air to allow
attachment of osteoblasts to the bottom of the wells.
Cellular activity was assessed by measuring mitochon-
drial succinic dehydrogenase (SDH) activity at several time
points to determine if trends in the biological response were
observable. Cytotoxicity was initially assessed for 24hr. After
this interval, the specimens were removed from the cell
culture, rinsed with sterile phosphate buﬀered saline (PBS),
and then immediately added to a second cell culture (which
had been plated with cells 24hrs earlier). This second culture
was incubated for 24hrs and the mitochondrial activity
assessed after incubation (48hrs reading). The specimens
were then removed again, rinsed again, and incubated in
cell culture medium without cells for 5 days at 37◦Ca n d
5%CO2. Finally, the specimens were rinsed again with PBS
and added to a third culture that had been plated with cells
24hrs before. The mitochondrial activity was then assessed
24hrs later (1wk reading).
At each of the three time points (24hrs, 48hrs, and
1wk), the cells were incubated for 24hrs in the presence
of the materials or Teﬂon discs (negative control) before
assessing cellular activity by measuring SDH activity. The
SDH activity, indicative of cellular mitochondrial function,
was measured by means of the MTT colorimetric assay [24].
Specimens were removed from each well, and the remaining
cells were washed carefully with 1.0mL of phosphate–
buﬀered saline (pH 7.4). A 1mg/mL MTT solution [3-(4,5-
dimethyl–thiazol-2-yl-) 2,5-diphenyl tetrazolium bromide-
succinate] was added for 45min at 37◦C, after which the
reaction was quenched with the addition of 0.5mL of 4%
Tris-formalin (pH 7.4) for 2-3min.
The MTT-formalin solution was removed and the cell
monolayer allowed to dry for 5–10min, then washed
in 1.0mL of water, and any MTT-formazan formed
by SDH activity in the cells was solubilized with 6%
dimethylsulfoxide–NaOH (0.1N NaOH in DMSO). An
aliquot of the resulting solution was transferred to a 96-
well ﬂat-bottomed tray and the optical density was measured
at 562nm (the absorption peak of the formazan) with
a microplate reader (MR 5000, Dynatech Laboratories,
Embrach-Embraport, Switzerland). The optical density of
the blank wells were subtracted from all wells, then the
formazan content of each well was computed as a percentage
of the Teﬂon control materials. Diﬀerences between groups
weredeterminedbyANOVAandTukeymultiplecomparison
intervals (α = 0.05).
2.7.3. Animal Experiments
(1) Implantation into Subcutaneous Connective Tissue. Fifty-
four ten-week-old male Wistar rats (Ratus norvegicus albi-
nus) weighing 200–250 grams obtained commercially and
given standard pellets and water ad libitum were used for the
implantationstudy. IACUCguidelines forthecareanduseof
laboratory animals were observed.
The animals were anesthetized by intramuscular admin-
istration of rodent anesthesia cocktail (1.5mL ketamine
HCl (100mg/mL), 1.5mL xylazine HCl (20mg/mL) andInternational Journal of Biomaterials 5
0.5mL acepromazine (10mg/mL) 0.2–0.5mL per 100g of
animal weight and stabilized on a surgical table. For the
implantation of the CPCs, the backs of the rats were shaved,
washed and disinfected with 5% iodine solution. Three
longitudinal incisions of about 1cm in length were made
throughthefullthicknessoftheskinusinganumber15blade
in a head-to-tail alignment orientation. Subsequently, lateral
to the incisions subcutaneous pockets were created by blunt
dissection with scissors. The experimental materials CPC-1
and CPC-2 weremixed at a powder to liquid ratio of 4:1 and
the commercial hydroxyapatite cement was mixed according
tothemanufactures’instructions.Cementswerethenpacked
in a cylindrical mould so that the paste samples were 4.7mm
in diameter and 10mm in length. The mould was made by
cutting the front portion of a 1cm3plastic syringe. A force of
approximately 0.5MPa was applied for packing the cement
paste into the moulds. After smoothing the surface of the
cement on the open side, cements were inserted randomly
into each subcutaneous pocket. These procedures were done
quickly so that the cement was implanted 1min after mixing.
Finally, the incisions were carefully closed with 3/0 silk
sutures.
Groupsofsixanimalspermaterialweresacriﬁcedat7,30
or 90 days after the implantation procedures.
After the experimental periods, all animals from each
group were anesthetized, the dorsal skin was shaved and dis-
infected, and the implants together with their surrounding
tissue were removed in blocks. Animals were killed by an
overdose of anesthetic immediately after removal of tissue
samples.
(2) Histological Preparation. The subcutaneous sites con-
taining the implants were carefully excised from the sur-
rounding tissue and immersed in buﬀered 10% formalin
ﬁxative solution for 48hrs. The biopsies were processed
for paraﬃn embedding. Six micrometer serial sections were
obtained and stained with hematoxylin and eosin. The
stained sections were assessed by light microscopy (Carl
Zeiss, Oberkachen, Germany).
Tissue reactions such as inﬂammatory response, thick-
ness of ﬁbrous capsule adjacent to the implanted material,
and the presence of macrophages and giant cells were
described based on a subjective single-blinded evaluation, as
previously reported in [25]. The histological event inﬂam-
matory reaction was recorded as: none, mild, moderate,
and severe, according to the inﬂammatory cell number
present close to the materials. To grade the inﬂammatory
reaction, ﬁve high-power magniﬁcation ﬁelds were selected
for all slides. The cell number was recorded with a grid
per high-power ﬁeld. The thickness of ﬁbrous capsule
formation was measured for each specimen using a light
microscope (Diastar, Cambridge Instruments, Buﬀalo, NY,
USA) adapted to a video-camera (DXC-107A/107P; Sony
Electronics, Inc, Tokyo, Japan) and to a microcomputer
and software (Mocha, Jandel Scientiﬁc, San Rafael, CA,
USA). Fibrous capsule formation thinner than 150μmw a s
scored as 1-thin. Fibrous capsule formation thicker than
150μm was recorded as 2-thick. Macrophages and giant cells
presence was recorded as 1-none, 2-mild, and 3-moderate,
Table 2: The Initial (I) and Final (F) setting times (inmin) of
hydroxyapatite cement and the two polymeric calcium phosphate
cements (CPCs) (values are means ±SD; n = 5).
Type
Initial
setting
time (min)
Final
setting
time (min)
Hydroxyapatite
cement (Control
group)
6 ±0.477 10 ±1.40
CPC-1 8 ±0.95 15 ±2.5
CPC-2 5 ±1.40 12 ±1.7
according to the number of these speciﬁc inﬂammatory cells
present close to the calcium phosphate materials, indicating
a persistent connective reaction against the implants. The
experimental materials were regarded as biocompatible if the
intensity of connective tissue reaction decreased over time.
Consequently, to be considered biocompatible, at 90 days
the connective tissue surrounding the implant must show
a thin ﬁbrous capsule formation as well as an absence of
inﬂammatory reaction and/or macrophages/giant cells. On
the other hand, the material was considered nonbiocompati-
blewhenapersistentinﬂammatoryreactionoccurredrelated
to macrophages and giant cells with a thick ﬁbrous capsule
development even at 90 days after implantation [25]. The
scores obtained from the histological assessment of sections
were submitted to the statistical analysis of Kruskal-Wallis
complemented by Mann-Whitney test taking into account a
level of signiﬁcance5%.
3. Results
3.1. Setting Time. The results of the initial and ﬁnal setting
times are presented in Table 2 and illustrated in Figure 1.
After mixing the powder and liquid components together,
the two polymeric cements One parameter to estimate the
setting of the cement is the setting time (ti: initial setting
time and tf: ﬁnal setting time) of the cement paste. The
setting time should be within a limited time range; 3 min <
ti < 8minandt f < 15min [26]. As illustrated in Figure 1,
under the conditions used, for polymeric calcium phosphate
cements (CPC-1 and CPC-2) such optimal settings were
achieved.
3.2. Mechanical Properties. T h em e a nv a l u e so fc o m p r e s s i v e
strength and diametral tensile strength of hydroxyapatite
cement (control group) and the two polymeric calcium
phosphate cements (CPC-1 and CPC-2) are listed in Tables 3
and 4 and illustrated graphically in (Figures 2 and 3).
3.2.1. Compressive Strength. At all the storage periods, from
30min to 2 weeks, the compressive strength values of
polymeric calcium phosphate cement (CPC-2) derived from
10%(w/w) aqueous solution of PA acid were higher than
that of hydroxyapatite cement (control) and CPC-1 cement
( P<. 05). When comparing the eﬀect of storage time6 International Journal of Biomaterials
Table 3: Mean compressive strength and standard deviation of hydroxyapatite cement and the two polymeric calcium phosphate cements
(CPCs) [the values in parenthesis are in MPa].
Cement Types 30 min 1hrs 4hrs 24hrs 1 week 2 weeks
Control Hydroxyapatite (1.38) ±0.18 (1.90) ±0.30 (4.13) ±0.70 (8.08) ±0.90 (13.41) ±2.10 (17.41) ±2.90
Calcium phosphate
Cements (CPCs)
CPC-1 (35.85) ±5.33 (40.42) ±3.25 (48.85) ±2.75 (71.68) ±2.80 (79.46) ±3.65 (67.12) ±4.12
CPC-2 (72.68) ±3.38 (75.12) ±3.55 (86.05) ±2.90 (90.57) ±4.09 (78.62) ±4.22 (73.59) ±3.10
LSD 5% 4.81∗ 2.36∗ 2.19∗ 3.30∗ 4.32∗ 3.22∗
∗Signiﬁcant at 5% level.
Table 4: Mean diametral tensile strength and standard deviation of hydroxyapatite cement and the two polymeric calcium phosphate
cements (CPCs) [the value in parenthesis are inMPa].
Cement Types 30min 1 hour 4hrs 24hrs 1 week 2 weeks
Control Hydroxyapatite cement (1.56) ±0.18 (1.86) ±0.30 (1. 96) ±0.40 (1.36) ±0.10 (2.99) ±0.80 (1.51) ±0.20
Calcium phosphate
Cements (CPCs)
CPC-1 (8.57) ±2.84 (11.43) ±2.41 (12.38) ±2.04 (13.81) ±2.36 (15.63) ±2.84 (13.77) ±2.89
CPC-2 (12.94) ±1.99 (15.75) ±1.44 (16.31) ±2.02 (21.12) ±2.99 (17.96) ±2.17 (17.28) ±2.89
LSD 5% 2.72∗ 2.72∗ 2.65∗ 2.63∗ 2.64∗ 2.84∗
∗Signiﬁcant at 5% level.
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Figure 1: Histogram showing the mean initial and ﬁnal setting
times (inmin) of hydroxyapatite cement and the two polymeric
calcium phosphate cements (CPCs).
on the compressive strength of the individual cements, the
compressive strength of hydroxyapatite cement signiﬁcantly
increased from 30min (1.38MPa) to 24hrs (8.08MPa), and
then signiﬁcantly increased up to 2 weeks (17.41MPa).
The mean value of compressive strength of (CPC-
1) polymeric CPC derived from 35% aqueous solu-
tion of (PMVE-Ma) signiﬁcantly increased from 30min
(35.85MPa) to 24hrs (71.68MPa), then slightly decreased
at the end of the second week (67.12MPa). The mean value
of compressive strength of (CPC-2) polymeric CPC derived
from PA signiﬁcantly increased from 30min (72.68MPa) up
to 4hrs (86.05MPa) then decreased at the end of the second
week (75.59MPa).
3.2.2. Diametral Tensile Strength. At all the storage periods
from 30min to 2 weeks, the mean diametral strength values
of polymeric calcium phosphate cement (CPC-2) derived
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Figure 2: Histogram showing the mean compressive strength of
hydroxyapatite cement and the two polymeric CPCs inMPa.
from 10%w/w aqueous solution of PA were higher than
that of hydroxyapatite cement and (CPC-2) cement (P<
.05). When comparing the eﬀect of storage time on the
mean values of diametral tensile strength, hydroxyapatite
cement showed the highest diametral strength values at the
end of the ﬁrst week (2.99MPa), then slightly decreased
at the end of the second week (1.51MPa). The mean
value of diametral tensile strength of (CPC-1) polymeric
CPC signiﬁcantly increased from 30min (8.57MPa) up to
one week (16.63MPa), then signiﬁcantly decreased at the
end of the second week (13.77MPa). The mean diametral
tensile strength value of (CPC-2) polymeric CPC cement
signiﬁcantly increased from 30min (12.94MPa) to 24hrs
(21.12MPa) then signiﬁcantly decreased at the end of the
second week (128.38kg/cm2)International Journal of Biomaterials 7
2weeks 1week 24hours 4hours 1hour 30min
Time
Hydroxyapatite cement
CPC-1
CPC-2
0
5
10
15
20
25
30
D
i
a
m
e
t
r
a
l
t
e
n
s
i
l
e
s
t
r
e
n
g
t
h
(
M
P
a
)
Figure 3: Histogram showing the mean diametral strength of
hydroxyapatite cement and the two polymeric CPCs inMPa
3.3.CellCulture(MTTAssay). Agingsigniﬁcantlyinﬂuenced
the cytotoxicity of the materials, which became less cytotoxic
over time (Figure 4). Overall, our results suggested signif-
icant diﬀerences between materials, and that cytotoxicity
generally decreases with time. Type I CPC was cytotoxic in
theinitial 24hrsoftesting, butSDHactivity hadsigniﬁcantly
(P<. 05), increased (>90%) and was statistically equivalent
t ot h en e g a t i v eT e ﬂ o nC o n t r o la f t e r1 w k .A t2 4 h r s ,C P C -
2 suppressed SDH activity by >55% relative to the Teﬂon
Control, and then showed some tendency toward an increase
in SDH activity with time (48hrs), although diﬀerences were
not statistically signiﬁcant. At 1wk, CPC-2 was signiﬁcantly
higher than the Teﬂon Control. Hydroxyapatite cement
suppressed SDH activity by 33%, and 85% relative to the
Teﬂon negative control after 24hrs and 48hrs, respectively,
and then showed a relapse by 35% after 1 week.
3.4.ImplantationintoSubcutaneousConnectiveTissueofRats.
The relationship among the periods of evaluation and the
connective tissue reaction (i.e. the presence of inﬂammatory
cells, formation of ﬁbrous capsule close to the implants, and
the presence of macrophages and giant cells) are given in
Table 5.
3.4.1. Seven Days. A similar histological characteristic
regarding the presence of macrophages and thickness of
the ﬁbrous capsule was demonstrated for all experimental
groups. Most of the samples exhibited thick capsules.
Also, in these samples, a mild presence of macrophages
adjacent to the implanted materials was observed (Figure 5
(a)). However, for CPC-1, CPC-2, and HA, a moderate
inﬂammatory reaction was demonstrated in 5, 4, and 3
samples, respectively. This inﬂammatory response mediated
by mononuclear cells (Figure 5 (b)) was also characterized
by the presence of a number of small congested and dilated
blood vessels, multinucleated giant cells, local edema, and
collagen degradation (Figures 5(c) and 5(d)). Only 1 sample
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Figure 4: Mitochondrial suppression induced by CPC-1, CPC-2,
andcommercialHA.Cytotoxicitywasevaluatedatthreetimepoints
24hrs, 48hrs and after 1wk. Succinic dehydrogenase activity was
measured and expressed as a percentage of Teﬂon Controls (deﬁned
as 100%). There were six replicates per condition. Diﬀerent letters
indicate a statistically signiﬁcant diﬀerence between the materials
(ANOVA, Tukey intervals α = 0.05)
of each experimental group exhibited a severe inﬂammatory
reaction (Table 5).
3.4.2. Thirty Days. For CPC-1, CPC-2, and HA, a mild
inﬂammatory reaction was observed for 3, 4, and 3 samples,
respectively (see Table 5). Most of these samples exhibited
a thin ﬁbrous capsule with a few macrophages adjacent to
the implanted calcium phosphate materials (Figure 6 (a)).
Those samples in which a persistent moderate inﬂammatory
reaction mediated by mononuclear cells occurred, a thick
capsule with several small blood vessels were observed
(Figure 6 (b)). Only one sample each of CPC-1 and HA
exhibited a moderate presence of macrophages adjacent to
the implanted materials (Figure 6 (c)).
3.4.3. Ninety Days. Connective tissue repair was observed
for all experimental materials. However complete healing
occurred only in 5 samples of those calcium phosphate
cements in which thin ﬁbrous capsule and lack of inﬂamma-
tory reaction were observed (Figure 7). One of each samples,
CPC-1 and HA exhibited a persistent inﬂammatory reaction.
In both samples, a zone of dispersed cement fragments (dis-
placement of the components of the experimental material)
wasobservedatagreatdistancefromtheimplants,triggering
a noticeable chronic connective tissue reaction. For HA, two
samples presented with a thick ﬁbrous capsule adjacent to
the implanted material. In these samples, a mild presence of
macrophages persisted.
Despite the more intense connective tissue reaction
observed for HA when compared to CPC-1 and CPC-2,
the statistical analysis of Kruskal-Wallis demonstrated that
there was no diﬀerence among the experimental groups8 International Journal of Biomaterials
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Figure 5:Tissuereactivitytoimplantedmaterialsat7days.(a)thisshowsmildinﬂammatoryreactionmediatedbymononuclearmonocytes
in response to the implanted CPC-1 (arrows). (b) Implanted CPC-2 at 7 days shows a moderate inﬂammatory reaction mediated by
mononuclear cells. (c) Implanted HA at 7 days exhibits an area of collagen degradation (arrows). (d) Example of the inﬂammatory reaction
characterized by small dilated blood vessels and presence of giant cells observed in response to all the implanted materials (CPC1 shown)
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Figure 6: Tissue reactivity to implanted materials at 30 days. (a) Note the thick ﬁbrous capsule (arrows) and the small dilated blood
vessels in response to the implanted material (CPC-1) (arrows). (b) CPC-2 at 30 days demonstrates a thin ﬁbrous capsule (arrows) and
few macrophages adjacent to the implanted material. (c) Area showing a moderate inﬂammatory reaction and a thin ﬁbrous capsule as seen
in CPC-2 and HA implanted materials (CPC-2 shown). H&E X200.International Journal of Biomaterials 9
Table 5: Scores determined for each histological feature according to the experimental and control groups and periods of evaluation.
(n = 6) 7 Days 30 Days 90 Days
CPC-1 CPC-2 HA CPC-1 CPC-2 HA CPC-1 CPC-2 HA
Inﬂammatory reaction
N o n e 0 000 003 53
M i l d 0 123 432 12
M o d e r a t e 5 433 231 01
S e v e r e 1 110 000 00
Fibrous capsule
T h i n 0 002 335 54
T h i c k 6 664 331 12
Macrophages/giant cells
N o n e 0 001 215 54
M i l d 4 554 441 12
M o d e r a t e 2 111 010 00
Connective tissue
Thin ﬁbrous capsule
Figure 7: Section of tissue from area of CPC-2 implantation which
demonstrates a thin ﬁbrous capsule and a normal connective tissue
denoting complete healing at 90 days. Note that this reaction is
typicalofallexperimentalimplantedmaterialsat90daysH/EX200.
regarding the histological features observed. According to
the periods of evaluation, a statistical signiﬁcant diﬀerence
was determined only between 7 and 90 days postoperative
time for all experimental groups (Mann-Whitney test, P<
.05). For CPC-1, a signiﬁcant diﬀerence in the presence of
macrophages and giant cells was observed when the periods
of 7 and 30 days were compared to the period of 90 days
4. Discussion
The advent of calcium phosphate bone cements (CPCs) is
considered as a remarkable development in the ﬁeld of bone
repair materials. Calcium phosphate bone cements (CPCs)
have been emerging as a new family of resorbable bone
substitutes since the mid 1980’s. However, problems such
as poor mechanical properties and relatively long setting
times which limits their clinical application are still encoun-
tered. Therefore, it is the ongoing objective of materials
development to improve (CPCs) and prepare compositions
with adequate mechanical properties and suitable setting
times. In this paper, we report the development of a calcium
phosphate bone cement suitable for orthopedic applications
with Tetracalcium phosphate (TTCP), dicalcium phosphate
dihydrate (DCPD), and Tricalcium phosphate Ca3(P04)2
as ingredients mixed with aqueous solutions of modiﬁed
polyacrylic acid (PA), polymethyl-vinyl ether-maleic acid
(PMVE-Ma)toimprovethephysicomechanicalpropertiesof
CPCs. All these selected materials are of medical grade, com-
mercially available, and have a well established compatibility.
An essential parameter considered before mixing these
essential components is to sieve each one separately up
to 80 microns, as reduction of particle size was found
to produce a substantial decrease of the setting time and
accelerate the hardening of the cement without signiﬁcantly
aﬀecting the ﬁnal strength attained [27]. Particle size can
also inﬂuence diﬀerent characteristics of materials, for
example an increased surface area (smaller particle size)
can lead to greater dissolution during the setting reaction
[28]; decreased working and setting times [29]; higher
compressive strength (CS); and higher diametral tensile
strength (DTS) [30].
Other essential criteria were also considered in relation
to the molecular weight and concentration of the aqueous
solutions used for mixing the powder, as higher molecular
weights tend to result in cements with shorter setting
times and higher compressive, diametral, and biaxial ﬂexural
strengths than their lower molecular weight counterparts
[31].
The polymethyl-vinyl ether-maleic anhydride (PMVE-
Ma) is a commercial copolymer oﬀered in several molecular
weights and can be dissolved by hydrolysis of the anhydride
group in water to form the corresponding maleic acid
copolymer (polymethyl-vinyl ether-maleic acid).
This copolymer has already a number of nondental
applications, in hair sprays and surgical adhesives which
suggest potentially favorable biocompatibility for dental and
other biomedical uses [15]. Because it is diﬃcult to form
workable cements from highly concentrated solutions of
PMVE-Maduetotheirhighviscosities,concentrationsabove
30% could not be investigated. However, aqueous solutions
of higher concentrations are feasible using lower molecular10 International Journal of Biomaterials
weight PMVE-Ma. In the present work, PMVE-Ma (50,000
molecular weight) was used in an aqueous solution of 35%
w/w [15]. PAA was used as an aqueous solution and diluted
with distilled water to obtain 10% w/w [32].
The addition of poly (acrylic acid), a water soluble
polymer, to CPC would be expected to result in a reaction
akin to the setting reaction in glass ionomer cements, which
wouldremedysomeoftheproblems.Inaddition,thebasicity
of TTCP is also expected to result in a rapid setting time
via the neutralization reaction, which in turn would result
in crosslinking of the polymers. In order to optimize the
powder/ liquid ratio of the mixing powder, preliminary
testingofvariouspowdermixtureratioswasperformeduntil
an optimal ratio of 4:1 was obtained.
4.1. Setting Time. There are two stages identiﬁed with the
setting of CPCs, the initial setting time which denotes the
end of the workability of the putty after wetting, and the
ﬁnal setting time which indicates hardening of the set mass
[33]. The manipulation of the setting times of CPCs is
signiﬁcant as they should meet the requirements of surgical
procedures. The initial setting should be easily adjusted so
as to allow a suﬃcient time gap for shaping and ﬁlling. After
theﬁlling,itisnotadvisabletodisturbthesetcementuntilits
hardening because any mechanical strain will produce cracks
and adversely aﬀect the strength. Therefore, CPCs require
the shortest possible ﬁnal setting time so that the wound
closure is not delayed. The presented results suggest that
calciumphosphatecementmixedwithpolymericliquidshad
a positive inﬂuence on the material setting properties and
the workability. CPC-1 mixed with PMVE-Ma acid (Table 2)
exhibited initial and ﬁnal setting times of, respectively, 8
and 15min. These results coincide with Dricssens et al. [26]
as recommended for orthopedic applications. As for CPC-2
mixed with modiﬁed polyacrylic acid, this cement showed
initial and ﬁnal setting times of 5 and 12min. Under the
operation procedures, the setting time should be within a
limited time range of 3min < ti < 8minandt f <15min [26].
Low diﬀerences between ti and tf improved the time scale of
the operation procedure.
4.2. Mechanical Properties. Results of the compressive and
diametral tensile strength values of the newly formulated
polymeric calcium phosphate cements are shown in Tables 3
and4.Thesearedenotedasoutstandingandimprovedvalues
when compared to hydroxyapatite bone cement (control
group).
In this study, the reaction between CPC powder and 35%
w/w (PMVE-Ma) aqueous solution resulted in a polymeric
CPC-I with compressive strength of 71.68MPa and diame-
tral strength of 13.8 1MPa 24hrs after mixing. These results
are in accordance with Matsuya et al. [15]. At the end of the
ﬁ r s tw e e km a x i m u ms t r e n g t hv a l u e sw e r er e a c h e d .
The cement prepared from CPC powder and modiﬁed
polyacrylic acid (CPC-2) had a compressive strength value
of 90.57MPa and diametral tensile strength of 16.3MPa,
4hrs after mixing and reached its maximum value at the end
of 24hrs. These high early strength values suggest that the
polymerization reaction is responsible for increasing of the
initial strength.
For the commercial hydroxyapatite cement, the set
cement has suﬃcient mechanical strength (17.41MPa) com-
parable to that of trabecular bone. These features make this
material suitable for applications as bone ﬁller.
Itwasapparentfrommechanicaltestingthatcompressive
strength (CS) and Diamertral Tensile Strength (DTS) were
inﬂuenced and positively correlated to the composition
of the cement powder. These results show that polymeric
liquidsimprovedthemechanicalpropertiesofcements,most
likely favored a better distribution of the mechanical load,
and therefore had the consequent greater values of mechan-
ical strength with respect to the control cement. Dramatic
improvements in mechanical properties were observed with
polyacrylic acid (PA) and polymethyl-vinyl ether-maleic acid
(PMVE-Ma) composite cements. Both systems exhibited
similar behavior. Polymeric calcium phosphate cements set
as the result of two reactions, the typical acid-base reaction,
and a polymerization reaction of polymer monomers. The
resulting structure is a cement matrix reinforced by the
interpenetrating chains of the polymer. These results suggest
that the cement-forming reaction of CPC-1 in the presence
of (PMVE-Ma) acid, TTCP mainly reacts with the carboxylic
acid groups of PMVE-Ma by ion exchange or an acid base
reaction. This setting mechanism was previously described
in other types of polymeric calcium phosphate cements [13].
Theamorphousreactionproduct,thatis,thepolysaltderived
from the reaction of PMVE-Ma with the CPC powder, forms
acementmatrixanalogoustothatformedinpolycarboxylate
or glass ionomer cements. The ﬁller phase of the polymeric
calcium phosphate cements consists of unreacted TTCP and
DCPA. The role of both TTCP and DCPA in this type of
polymeric cement may be that of reactive ﬁller.
The following formulation is proposed for the cement
forming reaction in the polymeric calcium phosphate
cement where R-COOH represents PMVE-Ma
R-COOH −→ R-COO
− +H + (1)
Ca4(PO4)2O+2H−→ 4Ca2+ +2 PO 4
3− +H 2O, (2)
2R-COOH+ Ca4(PO4)2O −→ R-COO-Ca-COO-R
+Ca 3(PO4)2 +H 2O,
(3)
Ca4(PO4)2O+ 2C a 3(PO4)2 +H 2O −→
Ca10(4 (PO4)6(OH)2.
(4)
Calcium ions are released from tetracalcium phosphate
powder by the dissolution/neutralization action of hydrogen
ions from PMVE-Ma, as shown in formulas (1)a n d( 2).
The Ca2+ ions from ionic cross links between the PMVE-Ma
molecules of the liquid component in the cement mixture
are shown in the reaction (3). The phosphate ions released
in reaction (2) remain in the cement matrix until the cement
is immersed in storage medium, where they can react with
calciumandphosphateionsreleasedbyhydrolysisofresidual
tetracalcuim phosphate to produce hydroxyapatite, as shown
in formula (4).International Journal of Biomaterials 11
The eﬀect of the molecular weight of PMVE-Ma present
in the liquid component is likely to have inﬂuenced the
compressive strength by virtue of the reinforcement that
can be provided by the elongated chains of the polymer
matrix. The high molecular weight (50,000) of the PMVE-
Ma, in addition to the highly branched structure allows it
to bridge numerous crystallites and engage in intermolecular
entanglements, providing strengthening mechanisms.
Nevertheless, the improved diametral tensile strength
(DTS) of PMVE-Ma composites (Table 4) clearly suggests
the polymer’s ability to absorb energy and bridge across
multiple crystallites. The strengthening eﬀect of polymeric
liquid relates to the fact that in brittle materials, the tensile
stress is indirectly controlled by fracture processes initiated
from preexisting distributions of ﬂaws and the reduction
of porosity related to the polymer addition which can
contribute to a signiﬁcant increase of the strength. Also,
the presence of a polymeric, second phase in the cement,
although in a small percentage, can result in an increase
of the crack propagation resistance. In addition, to the
positive eﬀect on diametral tensile strength of using CPC
powders having smaller-sized particles. These results are in
accordance with Matsuya et al. [15].
The cement forming reactions of CPC-2 in the presence
of polyacrylic (PA) acid are both neutralization and chela-
tion.Theneutralizationprocessoccursviathedissociationof
theH+ ionsfromthePolyacrylicacidsubunits,whichinturn
react with the basic TTCP thus enhancing the dissolution of
TTCP.Asaresult,Ca2+ ionsthenparticipateinacrosslinking
reaction resulting in the bridging of acrylic acid subunits
[34]. The resulting structure is a more tightly crosslinked
matrixreinforcedbytheinterpretatingchainsofthepolymer,
increasing compressive strength. Also, the diametral strength
of CPC-2 cement composites was signiﬁcantly enhanced due
to entanglement of the polymer chains in the cement matrix
and the reduction of crack propagation during failure as a
result of chain pullout, increasing mechanical strength.
The improvement in mechanical properties in both
cement composites can also be attributed to the powder
to liquid (P/L) ratio. It is well-known that the P/L ratio
aﬀects the ﬁnal mechanical properties of CPC, with an
increasedP/Lratioleadingtosuperiormechanicalproperties
and a concomitant reduction in working time and paste
workability [13, 35–37]. The increase in mechanical strength
due to an increase in P/L ratio is correlated with a lower
overallporosityoftheCPC[36,37].WhileP/Lratiomayplay
a role, the polymer’s chemical structure and the long chain
eﬀects are equally important.
4.3. Cell Culture Experiments. Although mechanical and
physicalpropertiesareofgreatconcernforbonereplacement
materials, biocompatibility is another critical issue. The
cytotoxicity of the two formulations of calcium phos-
phate cements and commercial Bone Source hydroxyapatite
cement were comparatively evaluated regarding the eﬀect
on cell proliferation and viability using the ROS17/2.8
osteoblast-like cell line originating from rat bone sarcoma.
These cells are well characterized, reproducible, and serve
as a good initial screening model for in vitro evaluation of
the biocompatibility of bone cements [38–40]. The MTT
assay, originally introduced in1983 by Mosmann [41], is
regarded as a sensitive method for the evaluation of the
cytotoxicity of biomaterials [42, 43]. This assay measures cell
proliferation and survival via mitochondrial dehydrogenase
activity, and is known to be easy, eﬃcient, and reliable
[41, 44]. The value of this type of study design is that
cytotoxicity of the materials can be observed under identical
conditions by allowing direct contact of the cells with the
tested materials [42]. This method also provides veriﬁcation
of degradation and/or the aﬀect of dissolution products on
cell viability and proliferation. In this way, this method can
replicate more closely the physiological situation in vivo.T h e
MTT assay showed that CPC-2 was the most biocompatible
material evaluated. The high biocompatibility presented by
this material and stimulation of the metabolic activity of the
cells in culture by CPC-2 after 1 week is not easily explained
and warrants further investigation.
Polymethyl-vinyl ether-maleic anhydride (PMVE-Ma)
is a commercial copolymer oﬀered in several molecular
weights and can be dissolved by hydrolysis of the anhydride
group in water to form the corresponding maleic copolymer
(polymethyl-vinylether-maleicacid).Theresultsofcytotoxi-
citytestingshowedthatCPC-1wasinitiallyseverelycytotoxic
to mitochondrial activity, but exhibited reduced cytotoxicity
over time. Therefore, it is possible that the initial suppression
of activity was caused by release of native mass from the
materials (unreacted polyacrylic acid). The polyacrylic acid
has a low pH and may leak gradually to the culture cells
causing this severe cytotoxicity. Over time, however, it is
possible that as cytotoxic elements were leached from the
material they either complexed with other molecules in the
medium or broke down, in each case rendering it more
biocompatible.
Hydroxyapatite (Bone Source) cement is a mixture of
CPCandanaqueoussolutionofphosphoricacid.Ourresults
showed an increase in SDH activity by 48hrs followed by
a relapse after 1 week which suggests an increase in release
of some material components that did not occur initially,
rendering the material more cytotoxic over time. The results
indicated are in agreement with Rossa et al. [45] whom
reported cytotoxicity of several formulations of calcium
phosphate cements due to the phosphoric acid present
in the liquid phase of the Hydroxyapatite (Bone Source)
formulation. The relapse in SDH activity could be explained
on the basis of: (a) the low pH value of the phosphoric acid.
may have led to a greater change in the pH of the culture
medium, resulting in more cellular damage (represented by
reducedviability),and(b)thecalciumphosphateparticlesin
the cement paste rapidly dissolved during the initial setting
reactionuptoacompleteconsumptionoftheacid;therefore,
the calcium and phosphate ion concentrations within the
cement liquid are dramatically increased, which may explain
the increase in cytotoxicity.
4.4. Implantation into Subcutaneous Connective Tissue of
Rats. Despite the diﬀerence between the materials observed
in vitro, there was no statistically signiﬁcant diﬀerence
between all groups regarding the in vivo biocompatibility. As12 International Journal of Biomaterials
previously reported, the surgical trauma caused during the
implantation may elicit an inﬂammatory reaction at short
time implantation [46]. However, it has also been reported
that the slow acid/base reaction that occurs in calcium
phosphate cements causes the maintenance of the low pH of
the material for extended periods of time [47].
Therefore, the persistently low pH of the set calcium
phosphates in contact to the connective tissue seems to play
an important role in the local connective tissue damage,
following the implantation procedure. As the connective
tissue reaction decreased with time, it may be suggested that
the edema adjacent to the set cements might neutralize the
eﬀects of the toxic low pH. On the other hand, the moist
environment (edema) interferes with the cement setting.
Therefore, most of the leached components of the material
including soluble ions or molecules and insoluble wear
debris and fragments may be displaced at a distance from
the implantation site to trigger the moderate to intense
inﬂammatoryresponseobservedattheshorttimeevaluation
(1wk). In conclusion, the initial inﬂammatory response may
be elicited by many diﬀerent irritant factors.
In the present investigation, it was shown that the
intensity and area of the inﬂammatory reaction decreased
with time. However, some samples each of CPC-1 and HA
exhibited macrophages and a few giant cells adjacent to the
implanted material even at the longest period of evaluation.
The more severe inﬂammatory response to CPC-1 and HA
may have been caused by the toxicity of the unreacted
polyacrylic acid leaching gradually to the surrounding tissue
also for HA cement this could be attributed to unreacted
phosphoric acid present in the liquid phase. In these
samples, zones of cement particles were dispersed from the
implantation site.
Previous in vivo studies demonstrated that large granules
of calcium phosphate ceramics become encapsulated by a
ﬁbrous tissue [48]. In contrast, small particles evoke an
intense localized inﬂammatory reaction, characterized by
the presence of multinucleated giant cells and macrophages
which in turn release inﬂammatory kinins like ﬁbroblast
growth factor and platelet derived growth factor which inﬂu-
ence ﬁbroblast behavior and subsequently induce thickening
of the ﬁbrous capsule [49–51]. Similar histological features
wereobservedinthepresentinvestigationsuggestingthatthe
cement particles, released into the wet environment after the
implantation procedure, triggered a persistent local chronic
inﬂammatory response. However, it may be speculated
that soluble calcium phosphate fragments released into the
connective tissue, might be removed by local lymphatic
drainage. This hypothesis should explain why the inﬂamma-
tory reaction decreased with time and the connective tissue
healing occurred for all experimental materials at 90 days
following the implantation.
One each of samples CPC-1 and HA presented a mod-
erate inﬂammatory reaction. In these samples, macrophages
and giant cells were observed engulﬁng globules and frag-
ments released from the implanted materials. Consequently,
it may be suggested that large particles of calcium phosphate
werenotremovedbythelocallymphaticdrainageordigested
by macrophages and giant cells. Consequently, the calcium
phosphate particles that remained in the connective tissue
may have triggered the persistent chronic inﬂammatory
reaction, which did not allow complete local connective
tissue healing.
The comparison among the data obtained from the
in vitro and in vivo tests in the present investigation
clearly demonstrate that both the time of elution and
material tested inﬂuenced cell respiratory activity. The newly
formulated CPC-1 and CPC-2 became less cytotoxic over
time. In contrast, the cytopathologic eﬀect evidenced by
the commercially available HA increased with time. For
the implantation methodology, the leachable components
of calcium phosphate cements contributed to the noticeable
initial aggressive eﬀects of these materials. However, with
time, connective tissue healing occurred characterizing the
in vivo biocompatibility of these materials. Therefore, it
is reasonable to assert that diﬀerences in the methods
used to evaluate the biocompatibility of biomaterials may
result in contradictory data as with results obtained for the
commercial HA cement.
The controversy between in vitro and in vivo studies to
evaluate the cytotoxic eﬀects and biocompatibility respec-
tively of biomaterials has been clearly demonstrated when
the results of such investigations are compared [52, 53].
The lack of correlation between in vitro tests and clinical
experience is probably related to many factors. The duration
of in vitro tests is probably a major factor since most in
vitro tests are relatively short time (3–7) days in duration.
As stated before above, an in vitro study should never be
considered a substitute for a clinical or experimental in vivo
evaluation. On the basis of our in vitro observations, we
conclude that the two formulations of calcium phosphate
cements tested CPC-1 and CPC-2 were comparable to the
commercially available positive control. Accordingly, the in
vivoobservations suggest that all calcium phosphate cements
evaluated may be considered as biocompatible following
implantation into the connective tissue of rats and appear
safe to use next to soft tissues.
ThetwopolymericCPCs(CPC-1andCPC-2)formulated
in the ﬁrst part of the study, demonstrated reasonable
setting times and high mechanical properties. By virtue of
these characteristics, coupled with their in vitro and in vivo
biocompatibility, CPC-1 and CPC-2 have properties that
show promise for orthopedic applications. CPC-1 and CPC-
2 should be further investigated in diﬀerent in vivo models
for speciﬁc applications such as vertebroplasty
References
[1] J. M. Rueger, “Bone replacement materials-state of the art and
the way ahead,” Orthopade, vol. 27, no. 1, pp. 72–91, 1998.
[2] P. D. Costantino and C. D. Friedman, “Synthetic bone graft
substitutes,” Otolaryngologic Clinics of North America, vol. 27,
no. 5, pp. 1037–1074, 1994.
[3] S. E. Groninger, C. Siew, L. C. Chow, A. O’Young, N. K. Ts’ao,
and W. E. Brown, “Evaluation of the biocompatibility of a new
calciumphosphatesettingcement,”J ournalo fDentalR esear ch,
vol. 63, abstract no. 200, 1984.
[ 4 ]W .E .B r o w na n dL .C .C h o w ,“ D e n t a lr e s t o r a t i v ec e m e n t
pastes,” US Patent no. 41518.430, 1985.International Journal of Biomaterials 13
[5] E. Fern´ andez, F. J. Gil, M. P. Ginebra, F. C. M. Driessens, J.
A. Planell, and S. M. Best, “Calcium phosphate bone cements
for clinical applications, part II: precipitate formation during
setting reactions,” Journal of Materials Science: Materials in
Medicine, vol. 10, no. 3, pp. 177–183, 1999.
[6] M. Bohner, “Calcium orthophosphates in medicine: from
ceramics to calcium phosphate cements,” Injury, vol. 31, no.
4, pp. D37–D47, 2000.
[7] C. D. Friedman, P. D. Costantino, S. Takagi, and L. C. Chow,
“BonesourceTM hydroxyapatite cement: a novel biomaterial
for craniofacial skeletal tissue engineering and reconstruc-
tion,” Journal of Biomedical Materials Research, vol. 43, no. 4,
pp. 428–432, 1998.
[8] J.P.Schmitz,J.O.Hollinger,andS.B.Milam,“Reconstruction
of bone using calcium phosphate bone cements: a critical
review,” Journal of Oral and Maxillofacial Surgery, vol. 57, no.
9, pp. 1122–1126, 1999.
[9] C. Durucan and P. W. Brown, “Low temperature formation
of calcium-deﬁcient hydroxyapatite-PLA/PLGA composites,”
Journal of Biomedical Materials Research, vol. 51, no. 4, pp.
717–725, 2000.
[10] C. Durucan and P. W. Brown, “Calcium-deﬁcient
hydroxyapatite-PLGA composites: mechanical and
microstructural investigation,” Journal of Biomedical Materials
Research, vol. 51, no. 4, pp. 726–734, 2000.
[11] Y. Fujishiro, K. Takahashi, and T. Sato, “Preparation and
compressive strength of α-tricalcium phosphate/gelatin gel
composite cement,” Journal of Biomedical Materials Research,
vol. 54, no. 4, pp. 525–530, 2001.
[12] K. Miyazaki, T. Horibe, J. M. Antonucci, S. Takagi, and L.
C. Chow, “Polymeric calcium phosphate cements: analysis of
reaction products and properties,” Dental Materials, vol. 9, no.
1, pp. 41–45, 1993.
[13] K. Miyazaki, T. Horibe, J. M. Antonucci, S. Takagi, and L.
C. Chow, “Polymeric calcium phosphate cements: setting
reaction modiﬁers,” Dental Materials, vol. 9, no. 1, pp. 46–50,
1993.
[ 1 4 ]L .A .D o sS a n t o s ,L .C .D eO l i v e i r a ,E .C .S .R i g o ,R .G .
Carrodeguas, A. O. Boschi, and A. C. F. De Arruda, “Inﬂuence
of polymeric additives on the mechanical properties of α-
tricalcium phosphate cement,” Bone, vol. 25, no. 1, pp. 99S–
102S, 1999.
[15] Y. Matsuya, J. M. Antonucci, S. Matsuya, S. Takagi, and L. C.
Chow, “Polymeric calcium phosphate cements derived from
poly(methyl vinyl ether-maleic acid),” Dental Materials, vol.
12, no. 1, pp. 2–7, 1996.
[16] International standard ISO 9917-1-2007 for water-based
cements.
[17] International standard ISO 4104-1984 (F) for zinc polycar-
boxylate cements.
[18] A. Bigi, E. Boanini, S. Panzavolta, and N. Roveri, “Biomimetic
growth of hydroxyapatite on gelatin ﬁlms doped with sodium
polyacrylate,” Biomacromolecules, vol. 1, no. 4, pp. 752–756,
2000.
[19] S. H. Dickens-Venz, S. Takagi, L. C. Chow, R. L. Bowen,
A. D. Johnston, and B. Dickens, “Physical and chemical
properties of resin-reinforced calcium phosphate cements,”
Dental Materials, vol. 10, no. 2, pp. 100–106, 1994.
[20] R. Craig, Restorative Dental Materials,C h a p t e r s4 ,8 ,M o s b y ,
Saint-Louis, Mo, USA, 11th edition, 1997.
[21] J. C. Wataha, F. A. Rueggeberg, C. A. Lapp et al., “In vitro
cytotoxicity of resin-containing restorative materials after
aginginartiﬁcialsaliva,” ClinicalOralInvestigations,vol.3,no.
3, pp. 144–149, 1999.
[22] International Organization for Standardization, “Biological
evaluation of medical devices. Part 5. Tests for cytotoxicity: in
vitro methods,” ISO 10993-5. Geneva, 1993.
[23] International Organization for Standardization, “Biological
evaluation of medical devices. Part 5. Tests for cytotoxicity: in
vitro methods,” ISO 10993-5. Geneva, 1992.
[24] J. C. Wataha, R. G. Craig, and C. T. Hanks, “Precision of and
new methods for testing in vitro alloy cytotoxicity,” Dental
Materials, vol. 8, no. 1, pp. 65–70, 1992.
[ 2 5 ]C .A .S .C o s t a ,H .M .T e i x e i r a ,A .B .L .N a s c i m e n t o ,a n dJ .
Hebling, “Biocompatibility of two current adhesive resins,”
Journal of Endodontics, vol. 26, no. 9, pp. 512–516, 2000.
[26] F. C. M. Dricssens, J. A. Flanell, M. G. Boltong, I. Khairoun,
and M. P. Ginebra, “Osteotransductive bone cements,” Pro-
ceedings of the Institution of Mechanical Engineers, vol. 212, no.
6, pp. 427–435, 1998.
[27] M. Jarcho, “Biomaterial aspects of calcium phosphates. Prop-
erties and applications,” Dental Clinics of North America, vol.
30, no. 1, pp. 25–47, 1986.
[28] L. H. Prentice, M. J. Tyas, and M. F. Burrow, “The eﬀect of
particle size distribution on an experimental glass-ionomer
cement,” Dental Materials, vol. 21, no. 6, pp. 505–510, 2005.
[29] A. Wren, O. M. Clarkin, F. R. Laﬃr, C. Ohtsuki, I. Y. Kim,
a n dM .R .T o w l e r ,“ T h ee ﬀect of glass synthesis route on
mechanical and physical properties of resultant glass ionomer
cements,” Journal of Materials Science: Materials in Medicine,
vol. 20, no. 10, pp. 1991–1999, 2009.
[30] D. Xie, W. A. Brantley, B. M. Culbertson, and G. Wang,
“Mechanical properties and microstructures of glass-ionomer
cements,” Dental Materials, vol. 16, no. 2, pp. 129–138, 2000.
[31] J. E. Barralet, L. M. Grover, and U. Gbureck, “Ionic mod-
iﬁcation of calcium phosphate cement viscosity. Part II:
hypodermic injection and strength improvement of brushite
cement,” Biomaterials, vol. 25, no. 11, pp. 2197–2203, 2004.
[32] Y. Miyamoto, K. Ishikawa, M. Takechi et al., “Non-decay type
fast-setting calcium phosphate cement: setting behaviour in
calf serum and its tissue response,” Biomaterials, vol. 17, no.
14, pp. 1429–1435, 1996.
[33] F. C. M. Driessens, M. G. Boltong, G. Bermudez, and J.
A. Planell, “Formulation and setting times of some calcium
orthophosphate cements, a pilot study,” Journal of Materials
Science: Materials in Medicine, vol. 1, pp. 502–516, 1993.
[34] A. O. Majekodunmi, J. W. Nicholson, and S. Deb, “Eﬀect
of molecular weight and concentration of poly(acrylic acid)
on the formation of a polymeric calcium phosphate cement,”
Biomaterials, vol. 17, no. 14, p. 1429, 1996.
[35] P. Boudeville, S. Serraj, J.-M. Leloup, J. Margerit, B. Pau-
vert, and A. Terol, “Physical properties and self-setting
mechanism of calcium phosphate cements from calcium
bis-dihydrogenophosphate monohydrate and calcium oxide,”
Journal of Materials Science: Materials in Medicine, vol. 10, no.
2, pp. 99–109, 1999.
[36] E. Fern´ andez, F. J. Gil, S. M. Best, M. P. Ginebra, F. C. M.
Driessens, and J. A. Planell, “Improvement of the mechan-
ical properties of new calcium phosphate bone cements in
the CaHO4-α-Ca3(PO4)2 system: compressive strength and
microstructuraldevelopment,”JournalofBiomedicalMaterials
Research, vol. 41, no. 4, pp. 560–567, 1998.
[37] K. E. Watson, K. S. Tenhuisen, and P. W. Brown, “The for-
mation of hydroxyapatite-calcium polyacrylate composites,”
Journal of Materials Science: Materials in Medicine, vol. 10, no.
4, pp. 205–213, 1999.
[38] Z. L. S. Sun, J. C. Wataha, and C. T. Hanks, “Eﬀects of metal
ions on osteoblast-like cell metabolism and diﬀerentiation,”14 International Journal of Biomaterials
Journal of Biomedical Materials Research, vol. 34, no. 1, pp. 29–
37, 1997.
[39] W. R. Snyder, J. Hoover, R. Khoury, and M. C. Farach-Carson,
“Eﬀect of agents used in perforation repair on osteoblastic
cells,” Journal of Endodontics, vol. 23, no. 3, pp. 158–161, 1997.
[40] M. Romanello, N. Bivi, A. Pines et al., “Bisphosphonates acti-
vate nucleotide receptors signaling and induce the expression
of Hsp90 in osteoblast-like cell lines,” Bone,v o l .3 9 ,n o .4 ,p p .
739–753, 2006.
[41] T. Mosmann, “Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
assays,” Journal of Immunological Methods,v o l .6 5 ,n o .1 - 2 ,p p .
55–63, 1983.
[42] H.SchweiklandG.Schmalz,“Toxicityparametersforcytotox-
icity testing of dental materials in two diﬀerent mammalian
cell lines,” European Journal of Oral Sciences, vol. 104, no. 3,
pp. 292–299, 1996.
[ 4 3 ]R .M .O s o r i o ,A .H e f t i ,F .J .V e r t u c c i ,a n dA .L .S h a w l e y ,
“Cytotoxicityofendodonticmaterials,”JournalofEndodontics,
vol. 24, no. 2, pp. 91–96, 1998.
[44] M. B. Hansen, S. E. Nielsen, and K. Berg, “Re-examination
and further development of a precise and rapid dye method
for measuring cell growth/cell kill,” Journal of Immunological
Methods, vol. 119, no. 2, pp. 203–210, 1989.
[45] C. Rossa Jr., E. Marcantonio Jr., L. A. Santos, A. O. Boschi,
and M. S. G. Raddi, “Cytotoxicity of two novel formulations
of calcium phosphate cements: a comparative in vitro study,”
Artiﬁcial Organs, vol. 29, no. 2, pp. 114–121, 2005.
[46] C. A. Costa, H. M. Teixeira, A. Batista Lopes Do Nascimento,
and J. Hebling, “Biocompatibility of two current adhesive
resins,” Journal of Endodontics, vol. 26, no. 9, pp. 512–516,
2000.
[47] M. Bohner, P. Van Landuyt, H. P. Merkle, and J. Lemaitre,
“Composition eﬀects on the pH of a hydraulic calcium
phosphate cement,” Journal of Materials Science: Materials in
Medicine, vol. 8, no. 11, pp. 675–681, 1997.
[ 4 8 ]B .D .R a t n e r ,A .S .H o ﬀman, F. J. Schoen, and J. E. Lemons,
“In vivo assessment of tissue compatibility,” in Biomaterials
Science, M. Spector and P. A. Lalor, Eds., pp. 222–223,
Academic Press, San Diego, Calif, USA, 1996.
[ 4 9 ] J .V a nd e rM e u l e na n dH .K .K o e rt e n ,“ I n ﬂ a m m a t o ryr e s p o n s e
and degradation of three types of calcium phosphate ceramic
in a non-osseous environment,” Journal of Biomedical Materi-
als Research, vol. 28, no. 12, pp. 1455–1463, 1994.
[ 5 0 ]L .C o m u z z i ,E .O o m s ,a n dJ .A .J a n s e n ,“ I n j e c t a b l ec a l c i u m
phosphate cement as a ﬁller for bone defects around oral
implants: an experimental study in goats,” Clinical Oral
Implants Research, vol. 13, no. 3, pp. 304–311, 2002.
[51] H. Yuan, Z. Yang, Y. Li, X. Zhang, J. D. De Bruijn, and K. De
Groot, “Osteoinduction by calcium phosphate biomaterials,”
Journal of Materials Science: Materials in Medicine, vol. 9, no.
12, pp. 723–726, 1998.
[52] A. Hensten-Pettersen and K. Helgeland, “Sensitivity of diﬀer-
ent human cell lines in the biologic evaluation of dental resin-
based restorative materials,” Scandinavian Journal of Dental
Research, vol. 89, no. 1, pp. 102–107, 1981.
[53] C. A. Costa, J. Hebling, and C. T. Hanks, “Current status of
pulp capping with dentin adhesive systems: a review,” Dental
Materials, vol. 16, no. 3, pp. 188–197, 2000.